BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20550223)

  • 21. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma.
    Lee CH; Wan Y; Smith A; Xie R; Motzer RJ
    Eur Urol Open Sci; 2021 Sep; 31():1-9. PubMed ID: 34467233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
    Alemao E; Rajagopalan S; Yang S; Curiel RE; Purvis J; Al MJ
    J Med Econ; 2011; 14(2):245-52. PubMed ID: 21417551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
    Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
    Value Health; 2010; 13(1):61-8. PubMed ID: 19804430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
    Plimack ER; Tan T; Wong YN; von Mehren MM; Malizzia L; Roethke SK; Litwin S; Li T; Hudes GR; Haas NB
    Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract]   [Full Text] [Related]  

  • 27. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
    Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
    Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
    Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
    Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temsirolimus: new drug. Metastatic kidney cancer: more assessment needed.
    Prescrire Int; 2008 Dec; 17(98):223-5. PubMed ID: 19415885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
    Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
    Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.
    Gerullis H; Bergmann L; Maute L; Ecke TH; Eimer C; Bagner JW; Otto T
    Med Oncol; 2010 Jun; 27(2):373-8. PubMed ID: 19399651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
    Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
    Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
    Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study.
    Sugiyama S; Sato K; Shibasaki Y; Endo Y; Uryu T; Toyoshima Y; Oya M; Miyanaga N; Saijo N; Gemma A; Akaza H
    Jpn J Clin Oncol; 2020 Aug; 50(8):940-947. PubMed ID: 32458996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.
    Miyake H; Harada K; Kusuda Y; Fujisawa M
    Int J Clin Oncol; 2013 Dec; 18(6):1054-9. PubMed ID: 23114786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
    Radice D; Redaelli A
    Pharmacoeconomics; 2005; 23(1):69-75. PubMed ID: 15693729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
    Lee CK; Marschner IC; Simes RJ; Voysey M; Egleston B; Hudes G; de Souza P
    Clin Cancer Res; 2012 Jun; 18(11):3188-96. PubMed ID: 22472176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.